Schellenberg Wittmer: SGI in a capital commitment of USD 4.5m
Schellenberg Wittmer acted as Swiss counsel to SPRIM Global Investments (SGI), a leading health sciences venture capital firm, in its capital commitment of USD 4.5 million in favor of Spexis, a clinical-stage and biopharmaceutical company listed on the SIX Swiss Exchange, to enable initiation of ColiFin® Phase 3 study. The commitment was structured as a mix of secured debt and subordinated debt mandatorily converting into equity.
The team consisted of Tarek Houdrouge (overall lead, pictured), Jérémie Tenot (banking & finance) and Alexander Zundel (corporate/m&a).